6:24 PM
 | 
Dec 20, 2013
 |  BC Extra  |  Company News

FDA says no decision yet for Amarin's Vascepa

Amarin Corp. plc (NASDAQ:AMRN) said FDA notified the company that the agency will not make a decision on an sNDA seeking to expand the label of hypertriglyceridemia drug Vascepa icosapent ethyl by the Friday PDUFA date. The company is seeking to...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >